MTOR and melanoma: Studies have found that knockdown of B7-H3 in metastatic melanoma tissue increases the sensitivity of melanoma cells to chemotherapy with dacarbazine (DTIC), binimetinib (MEK inhibitor), everolimus (mTOR inhibitor), and triciribine (AKT inhibitor) (135).